Enzon Pharmaceuticals Inc (ENZN)
0.0795
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 5.900M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -43.21% |
Valuation | |
PE Ratio | 60.73 |
PE Ratio (Forward) | Upgrade |
PS Ratio | -- |
Price to Book Value | 2.136 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 92.81% |
Profile
Enzon Pharmaceuticals Inc is positioned as a public company acquisition vehicle, where the Company can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value. |
URL | http://www.enzon.com |
Investor Relations URL | N/A |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 09, 2025 (est.) |
Last Earnings Release | Nov. 05, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Sep. 30, 2019 |
Ratings
Profile
Enzon Pharmaceuticals Inc is positioned as a public company acquisition vehicle, where the Company can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value. |
URL | http://www.enzon.com |
Investor Relations URL | N/A |
HQ State/Province | New Jersey |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 09, 2025 (est.) |
Last Earnings Release | Nov. 05, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | Sep. 30, 2019 |